Zollinger–Ellison syndrome: Presentation, response to therapy, and outcome

Wilcox, C. Mel; Seay, Toni; Arcury, Justin T.; Mohnen, Jean; Hirschowitz, Basil I.

doi:10.1016/j.dld.2010.11.007

Cited by 35 publications

(23 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, many surgical recommendations come from extensive work performed at the NIH, 4,8,9,12,14,22,30,31 although a few comprehensive long-term studies have come from tertiary care centers where many of these patients are treated. [27][28][29] Second, the clinical course is highly unpredictable. There have been conflicting data regarding primary tumor type, 8,20,35,36 presence of MEN-1 syndrome, 20,35,37-41 sex, and initial serum gastrin level 8 as predictive of malignant potential.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Importance of Surveillance for Multiple Endocrine Neoplasia-1 and Surgery in Patients With Sporadic Zollinger–Ellison Syndrome

Singh

Fraker

Metz

2012

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Other groups avoid surgery altogether, instead choosing to control GAH alone. [25][26][27] Most, but not all, [27][28][29] of the current surgical recommendations reflect extensive research from the NIH, 4,8,9,12,14,22,30,31 and therefore may not be directly applicable to tertiary care centers managing these patients according to different protocols.…”

mentioning

confidence: 99%

Importance of Surveillance for Multiple Endocrine Neoplasia-1 and Surgery in Patients With Sporadic Zollinger–Ellison Syndrome

Singh

Fraker

Metz

2012

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

“…Fortunately, this does not influence the outcome and should not withhold patients from surgery (Alexander et al 1998, Norton et al 2012. A sharp decrease in peptic complications in ZES has been established since the introduction of PPIs leading to a discussion if surgery is indicated for ZES (Hirschowitz et al 2005, Wilcox et al 2011. Treatment strategy is also highly dependent on the presence or absence of the multiple endocrine neoplasia 1 (MEN-1) syndrome.…”

Section: Gastrinomamentioning

confidence: 99%

Effect of hormone secretory syndromes on neuroendocrine tumor prognosis

Zandee

Kamp

Adrichem

et al. 2017

Endocrine-Related Cancer

View full text Add to dashboard Cite

The treatment of hormone hypersecretory syndromes caused by neuroendocrine tumors (NETs) can be a major challenge. NETs originating from the small intestine often secrete serotonin causing flushing, diarrhea and valve fibrosis, leading to dehydration or heart failure in severe cases. NETs from the pancreas can secrete a wider variety of hormones, like insulin, glucagon and gastrin leading to distinct clinical syndromes. Historically mortality in patients with functioning NETs was high due to the complications caused by the hypersecretion of hormones. This has been reduced with several drugs: protonpump inhibitors decrease acid secretion caused by gastrinomas. Somatostatin analogs can inhibit the secretion of multiple hormones and these are now the cornerstone for treating patients with a gastroenteropancreatic NET. However, peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs and everolimus can also decrease symptoms of hypersecretion and increase progression-free survival. Several factors affect the survival in patients with a functioning NET. Complications of hypersecretion negatively impact survival; however, secretion of hormones is also often a sign of a well-differentiated NET and due to the symptoms, functioning NETs can be detected in an earlier stage suggesting a positive effect on prognosis. The effect on survival is also dependent on the type of hormone being secreted. This review aims to study the effect of hormone secretion on the prognosis of NETs with the contemporary treatments options available today.

show abstract

“…In the case of hormonally functional tumours with characteristics of gastrinoma, upper gastrointestinal endoscopy may demonstrate specific lesions associated with gastric hypersecretion, such as multiple gastric and duodenal ulcers, and even small intestinal ulcers, or severe reflux oesophagitis (Zollinger-Ellison syndrome) [6,47].…”

Section: Neuroendocrine Neoplasms Of the Duodenummentioning

confidence: 99%